TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro.
The host restriction factor TRIM5alpha provides intrinsic defense against retroviral infections in mammalian cells. TRIM5alpha blocks infection by targeting the viral capsid after entry but prior to completion of reverse transcription, but whether this interaction directly alters the structure of the viral capsid is unknown. A previous study reported that rhesus macaque TRIM5alpha protein stably associates with cylindrical complexes formed by assembly of recombinant HIV-1 CA-NC protein in vitro and that restriction leads to accelerated HIV-1 uncoating in target cells. To gain further insight into the mechanism of TRIM5alpha-dependent restriction, we examined the structural effects of TRIM5 proteins on preassembled CA-NC complexes by electron microscopy. Incubation of assembled complexes with lysate of cells expressing the restrictive rhesus TRIM5alpha protein resulted in marked disruption of the normal cylindrical structure of the complexes. In contrast, incubation with lysate of control cells or cells expressing comparable levels of the nonrestrictive human TRIM5alpha protein had little effect on the complexes. Incubation with lysate of cells expressing the TRIMCyp restriction factor also disrupted the cylinders. The effect of TRIMCyp was prevented by the addition of cyclosporine, which inhibits binding of TRIMCyp to the HIV-1 capsid. Thus, disruption of CA-NC cylinders by TRIM5alpha and TRIMCyp was correlated with the specificity of restriction. Collectively, these results suggest that TRIM5alpha-dependent restriction of HIV-1 infection results from structural perturbation of the viral capsid leading to aberrant HIV-1 uncoating in target cells.
Black
Lesa R
LR
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, A-5301 Medical Center North, Nashville, TN 37232-2363, USA.
Aiken
Christopher
C
D000818:Animals; D000090103:Antiviral Restriction Factors; D002213:Capsid / Q000276:immunology* / Q000648:ultrastructure*; D002352:Carrier Proteins / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology* / Q000648:ultrastructure*; D006801:Humans; D008253:Macaca mulatta; D046529:Microscopy, Electron, Transmission; D011506:Proteins / Q000276:immunology*; D000070584:Tripartite Motif Proteins; D044767:Ubiquitin-Protein Ligases
D000090103:Antiviral Restriction Factors; D002352:Carrier Proteins; D011506:Proteins; D000070584:Tripartite Motif Proteins; C477346:TRIM5 protein, human; C482587:TRIM5(alpha) protein, rhesus monkey; D044767:Ubiquitin-Protein Ligases
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10774-9
15249685
FEBS J. 2008 Apr;275(7):1540-1555
18312418
J Virol. 2005 Dec;79(24):15567-72
16306627
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11827-32
15280539
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13324-8
15326303
Virology. 2006 Jul 20;351(1):112-20
16643975
Nat Rev Microbiol. 2005 Oct;3(10):799-808
16175175
Cell. 1993 Jun 18;73(6):1067-78
8513493
Retrovirology. 2005 Jun 20;2:40
15967037
Nature. 1994 Nov 24;372(6504):363-5
7969495
Nat Immunol. 2004 Nov;5(11):1109-15
15496950
Proc Natl Acad Sci U S A. 2006 May 9;103(19):7465-70
16648264
Nature. 1994 Nov 24;372(6504):359-62
7969494
J Virol. 2005 Nov;79(22):14446-50
16254380
Virology. 2006 Sep 30;353(2):396-409
16828831
Nature. 2004 Jul 29;430(6999):569-73
15243629
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11920-5
12154231
J Virol. 2002 Jun;76(11):5667-77
11991995
Mol Ther. 2005 Oct;12(4):687-96
16081321
J Virol. 2006 Sep;80(17):8554-65
16912305
J Virol. 2004 Nov;78(21):11739-50
15479815
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3569-74
18287033
J Virol. 2005 Aug;79(16):10571-7
16051849
J Virol. 2005 Jan;79(1):176-83
15596813
J Virol. 2009 Oct;83(20):10737-51
19656869
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3563-8
18287034
Mol Cell. 2004 Dec 22;16(6):849-59
15610729
AIDS. 2007 Dec;21 Suppl 8:S19-26
18172386
Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5514-9
16540544
Exp Cell Res. 2003 Aug 1;288(1):84-93
12878161
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10780-5
15249687
J Virol. 2005 Jan;79(2):869-75
15613315
J Virol. 2007 Oct;81(19):10362-78
17626085
J Virol. 2005 Dec;79(24):15175-88
16306589
Science. 1999 Jan 1;283(5398):80-3
9872746
PLoS Pathog. 2008 May 23;4(5):e1000074
18497858
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10786-91
15249690
Nat Med. 2003 Sep;9(9):1138-43
12897779
J Virol. 2008 Dec;82(23):11682-94
18799573
J Virol. 2007 Mar;81(5):2138-48
17135314
J Virol. 2008 Dec;82(23):11495-502
18799578
Virology. 2006 Jul 5;350(2):493-500
16624363
J Virol. 2005 Jul;79(14):8870-7
15994780
J Mol Biol. 1997 Jun 27;269(5):780-95
9223641
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13843-8
12368468
J Virol. 2005 Mar;79(5):3139-45
15709033
Curr Biol. 2005 Jan 11;15(1):73-8
15649369
J Virol. 2003 Dec;77(24):13403-6
14645596
J Biol Chem. 2005 Jul 22;280(29):26933-40
15897199
J Virol. 2005 Apr;79(7):3930-7
15767395
J Virol. 2005 Jul;79(14):8969-78
15994791
Nature. 2004 Feb 26;427(6977):848-53
14985764
EMBO J. 2001 May 1;20(9):2140-51
11331580
J Virol. 2005 May;79(10):6111-21
15857996
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3557-62
18287035